Skip to main content
Top
Published in: Clinical Rheumatology 4/2015

01-04-2015 | Original Article

The value of FDG-PET in the diagnosis of thromboangiitis obliterans—a case series

Authors: Gerald Hackl, Robert Milosavljevic, Klara Belaj, Thomas Gary, Peter Rief, Franz Hafner, Rainer W. Lipp, Marianne Brodmann

Published in: Clinical Rheumatology | Issue 4/2015

Login to get access

Abstract

Thromboangiitis obliterans (TAO) is an inflammatory vascular disease affecting dominantly the vessels of the extremities and is etiologically strongly associated with tobacco consumption. Different imaging techniques are generally used to exclude potential differential diagnoses. We investigated the value of 18 F-flourodeoxyglucose positron emission tomography ([18 F]FDG-PET) in the diagnosis of TAO. All consecutive patients with diagnosed TAO between Nov 2001 and Nov 2003 at our institution who underwent [18 F]FDG-PET in the diagnostic workup were analyzed retrospectively. Whole-body scans were conducted after a fasting period of at least 6 h and blood glucose levels lower than 180 mg/dl. The primary endpoint was defined as significantly increased vascular FDG uptake. Tracer uptake was visually determined and, in accordance with strength, divided into grades 0 to 3. In total, ten patients were statistically evaluated. The median patient age at the date of the first [18 F]FDG-PET was 41.5 years. Repetitive FDG-PET imaging was performed in seven out of ten patients (70 %). The endpoint was objectified in one of the initial examinations (10 %) and in another one out of seven follow-up scans (14.3 %). One positive [18 F]FDG-PET was observed in the pelvic vessels and the other in the infrapopliteal arteries. Therefore, increased tracer uptake could be observed in two examinations on two different patients (both with grade 3 tracer uptake) out of 17 conducted [18 F]FDG-PETs in total. The [18 F]FDG-PET was not a suitable investigative procedure for the diagnosis of TAO in the present patient cohort.
Literature
1.
go back to reference Zerizer I, Tan K, Khan S, Barwick T, Marzola MC, Rubello D, Al-Nahhas A (2010) Role of FDG-PET and PET/CT in the diagnosis and management of vasculitis. Eur J Radiol 73:504–509CrossRefPubMed Zerizer I, Tan K, Khan S, Barwick T, Marzola MC, Rubello D, Al-Nahhas A (2010) Role of FDG-PET and PET/CT in the diagnosis and management of vasculitis. Eur J Radiol 73:504–509CrossRefPubMed
2.
4.
go back to reference Cachovan M (1988) Epidemiologie und geographisches Verteilungsmuster der Thromboangiitis obliterans. In: Heidrich J (ed) Thromboangiitis obliterans morbus Winiwarter-Buerger, George Thieme. Stuttgart, New York, pp 31–36 Cachovan M (1988) Epidemiologie und geographisches Verteilungsmuster der Thromboangiitis obliterans. In: Heidrich J (ed) Thromboangiitis obliterans morbus Winiwarter-Buerger, George Thieme. Stuttgart, New York, pp 31–36
5.
go back to reference Shionoya S (1998) Diagnostic criteria of Buerger’s disease. Int J Cardiol 66(Suppl 1):S243–S245, discussion S247CrossRefPubMed Shionoya S (1998) Diagnostic criteria of Buerger’s disease. Int J Cardiol 66(Suppl 1):S243–S245, discussion S247CrossRefPubMed
6.
go back to reference Brodmann M, Lipp RW, Passath A, Seinost G, Pabst E, Pilger E (2004) The role of 2-18 F-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of giant cell arteritis of the temporal arteries. Rheumatology (Oxford) 43:241–242CrossRef Brodmann M, Lipp RW, Passath A, Seinost G, Pabst E, Pilger E (2004) The role of 2-18 F-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of giant cell arteritis of the temporal arteries. Rheumatology (Oxford) 43:241–242CrossRef
7.
go back to reference Blockmans D, Stroobants S, Maes A, Mortelmans L (2000) Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 108:246–249CrossRefPubMed Blockmans D, Stroobants S, Maes A, Mortelmans L (2000) Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 108:246–249CrossRefPubMed
8.
go back to reference Beggs AD, Hain SF (2002) F-18 FDG-positron emission tomographic scanning and Wegener’s granulomatosis. Clin Nucl Med 27:705–706CrossRefPubMed Beggs AD, Hain SF (2002) F-18 FDG-positron emission tomographic scanning and Wegener’s granulomatosis. Clin Nucl Med 27:705–706CrossRefPubMed
9.
go back to reference Ueda N, Inoue Y, Himeji D, Shimao Y, Oryoji K, Mitoma H, Arinobu Y, Niiro H, Tsukamoto H, Horiuchi T, Ueda A, Akashi K (2010) Wegener’s granulomatosis detected initially by integrated 18 F-fluorodeoxyglucose positron emission tomography/computed tomography. Mod Rheumatol 20:205–209CrossRefPubMed Ueda N, Inoue Y, Himeji D, Shimao Y, Oryoji K, Mitoma H, Arinobu Y, Niiro H, Tsukamoto H, Horiuchi T, Ueda A, Akashi K (2010) Wegener’s granulomatosis detected initially by integrated 18 F-fluorodeoxyglucose positron emission tomography/computed tomography. Mod Rheumatol 20:205–209CrossRefPubMed
10.
go back to reference Bleeker-Rovers CP, Bredie SJ, van der Meer JW, Corstens FH, Oyen WJ (2003) F-18-fluorodeoxyglucose positron emission tomography in diagnosis and follow-up of patients with different types of vasculitis. Neth J Med 61:323–329PubMed Bleeker-Rovers CP, Bredie SJ, van der Meer JW, Corstens FH, Oyen WJ (2003) F-18-fluorodeoxyglucose positron emission tomography in diagnosis and follow-up of patients with different types of vasculitis. Neth J Med 61:323–329PubMed
11.
go back to reference Weinberg I, Jaff MR (2012) Nonatherosclerotic arterial disorders of the lower extremities. Circulation 126:213–222CrossRefPubMed Weinberg I, Jaff MR (2012) Nonatherosclerotic arterial disorders of the lower extremities. Circulation 126:213–222CrossRefPubMed
12.
go back to reference Suzuki S, Yamada I, Himeno Y (1996) Angiographic findings in Buerger disease. Int J Cardiol 54(Suppl):S189–S195CrossRefPubMed Suzuki S, Yamada I, Himeno Y (1996) Angiographic findings in Buerger disease. Int J Cardiol 54(Suppl):S189–S195CrossRefPubMed
13.
go back to reference Fujii Y, Soga J, Nakamura S, Hidaka T, Hata T, Idei N, Fujimura N, Nishioka K, Chayama K, Kihara Y, Higashi Y (2010) Classification of corkscrew collaterals in thromboangiitis obliterans (Buerger’s disease): relationship between corkscrew type and prevalence of ischemic ulcers. Circ J 74:1684–1688CrossRefPubMed Fujii Y, Soga J, Nakamura S, Hidaka T, Hata T, Idei N, Fujimura N, Nishioka K, Chayama K, Kihara Y, Higashi Y (2010) Classification of corkscrew collaterals in thromboangiitis obliterans (Buerger’s disease): relationship between corkscrew type and prevalence of ischemic ulcers. Circ J 74:1684–1688CrossRefPubMed
14.
go back to reference Fujii Y, Soga J, Hidaka T, Hata T, Idei N, Fujimura N, Mikami S, Maruhashi T, Kihara Y, Noma K, Higashi Y (2011) Color doppler flows of corkscrew collaterals in Thromboangiitis obliterans (Buerger’s disease) using color duplex ultrasonography. J Am Coll Cardiol 57:2539CrossRefPubMed Fujii Y, Soga J, Hidaka T, Hata T, Idei N, Fujimura N, Mikami S, Maruhashi T, Kihara Y, Noma K, Higashi Y (2011) Color doppler flows of corkscrew collaterals in Thromboangiitis obliterans (Buerger’s disease) using color duplex ultrasonography. J Am Coll Cardiol 57:2539CrossRefPubMed
15.
go back to reference Fujii Y, Nishioka K, Yoshizumi M, Chayama K, Higashi Y (2007) Images in cardiovascular medicine Corkscrew collaterals in thromboangitis obliterans (Buerger’s disease). Circulation 116:e539–e540CrossRefPubMed Fujii Y, Nishioka K, Yoshizumi M, Chayama K, Higashi Y (2007) Images in cardiovascular medicine Corkscrew collaterals in thromboangitis obliterans (Buerger’s disease). Circulation 116:e539–e540CrossRefPubMed
16.
go back to reference Bauer T, Rauber K, Rau WS (1990) Differential diagnosis of acral blood circulation disorders using intra-arterial DSA of the hand. Rofo 152:271–276CrossRefPubMed Bauer T, Rauber K, Rau WS (1990) Differential diagnosis of acral blood circulation disorders using intra-arterial DSA of the hand. Rofo 152:271–276CrossRefPubMed
17.
go back to reference Hasegawa M, Nagai Y, Tamura A, Ishikawa O (2006) Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br J Dermatol 155:1159–1164CrossRefPubMed Hasegawa M, Nagai Y, Tamura A, Ishikawa O (2006) Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br J Dermatol 155:1159–1164CrossRefPubMed
18.
19.
go back to reference Muci-Mendoza R, Ramella M, Fuenmayor-Rivera D (2002) Corkscrew retinal vessels in neurofibromatosis type 1: report of 12 cases. Br J Ophthalmol 86:282–284CrossRefPubMedCentralPubMed Muci-Mendoza R, Ramella M, Fuenmayor-Rivera D (2002) Corkscrew retinal vessels in neurofibromatosis type 1: report of 12 cases. Br J Ophthalmol 86:282–284CrossRefPubMedCentralPubMed
20.
go back to reference Larsen BT, Edwards WD, Jensen MH, Johnson CH, McBane RD, Harmsen WS, Maleszewski JJ (2013) Surgical pathology of hypothenar hammer syndrome with new pathogenetic insights: a 25-year institutional experience with clinical and pathologic review of 67 cases. Am J Surg Pathol 37:1700–1708CrossRefPubMed Larsen BT, Edwards WD, Jensen MH, Johnson CH, McBane RD, Harmsen WS, Maleszewski JJ (2013) Surgical pathology of hypothenar hammer syndrome with new pathogenetic insights: a 25-year institutional experience with clinical and pathologic review of 67 cases. Am J Surg Pathol 37:1700–1708CrossRefPubMed
21.
go back to reference Belhocine T, Blockmans D, Hustinx R, Vandevivere J, Mortelmans L (2003) Imaging of large vessel vasculitis with (18)FDG PET: illusion or reality? A critical review of the literature data. Eur J Nucl Med Mol Imaging 30:1305–1313CrossRefPubMed Belhocine T, Blockmans D, Hustinx R, Vandevivere J, Mortelmans L (2003) Imaging of large vessel vasculitis with (18)FDG PET: illusion or reality? A critical review of the literature data. Eur J Nucl Med Mol Imaging 30:1305–1313CrossRefPubMed
22.
go back to reference Bural GG, Torigian DA, Chamroonrat W, Houseni M, Chen W, Basu S, Kumar R, Alavi A (2008) FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging 35:562–569CrossRefPubMed Bural GG, Torigian DA, Chamroonrat W, Houseni M, Chen W, Basu S, Kumar R, Alavi A (2008) FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging 35:562–569CrossRefPubMed
23.
go back to reference Shionoya S, Ban I, Nakata Y, Matsubara J, Hirai M, Kawai S (1978) Involvement of the iliac artery in Buerger’s disease (pathogenesis and arterial reconstruction). J Cardiovasc Surg (Torino) 19:69–76 Shionoya S, Ban I, Nakata Y, Matsubara J, Hirai M, Kawai S (1978) Involvement of the iliac artery in Buerger’s disease (pathogenesis and arterial reconstruction). J Cardiovasc Surg (Torino) 19:69–76
24.
Metadata
Title
The value of FDG-PET in the diagnosis of thromboangiitis obliterans—a case series
Authors
Gerald Hackl
Robert Milosavljevic
Klara Belaj
Thomas Gary
Peter Rief
Franz Hafner
Rainer W. Lipp
Marianne Brodmann
Publication date
01-04-2015
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 4/2015
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2648-5

Other articles of this Issue 4/2015

Clinical Rheumatology 4/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine